Bevacizumab

Bevacizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Advanced Endometrial Carcinoma、Recurrent Endometrial Carcinoma、Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma、Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Bevacizumab 研究

• Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)

  不适用招募中中国NCT07627347

• Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

  III 期招募中中国NCT06008119

• Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

  II 期招募中中国NCT06928584

• A Phase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC

  II 期招募中中国NCT06844474

• Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

  II 期招募中美国Czechia德国意大利NCT06607458

• Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi

  II 期招募中中国NCT05551208

• Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU

  II 期招募中中国NCT07391618

• Creation of a Clinical Database on Primary Nervous System Tumors

  不适用招募中法国NCT04516720

• A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

  I 期 / II 期招募中中国NCT06840002

• QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

  II 期招募中中国NCT07327788

• A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

  I 期 / II 期招募中美国ChileIsrael日本NCT05584670

• AB122 Platform Study

  I 期招募中日本NCT04999761

• Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Study

  不适用招募中Turkey (Türkiye)NCT07821450

• A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM

  II 期招募中中国NCT06590259

• Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

  II 期招募中中国中国香港NCT07023484

• A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

  II 期招募中中国NCT07054567

• Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

  II 期招募中意大利NCT07276100

• Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

  I 期 / II 期招募中中国NCT07080216

• RC48 in Combination With AK104 and Bevacizumab in OCCC

  II 期招募中中国NCT06540729

• A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  I 期招募中美国加拿大中国法国NCT06131840

• Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma

  II 期招募中中国台湾NCT06339424

• FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis

  II 期招募中中国NCT06801665

• Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

  II 期招募中RussiaNCT07130032

• A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

  III 期招募中中国台湾NCT06496971

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。